Envestnet Portfolio Solutions Inc. Sells 5,855 Shares of Hologic, Inc. (NASDAQ:HOLX)

Envestnet Portfolio Solutions Inc. trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 28.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,617 shares of the medical equipment provider's stock after selling 5,855 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Hologic were worth $1,054,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter valued at $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock valued at $27,000 after acquiring an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares during the period. First Horizon Advisors Inc. increased its position in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock worth $39,000 after acquiring an additional 134 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages recently commented on HOLX. Jefferies Financial Group started coverage on Hologic in a research note on Tuesday, December 10th. They issued a "hold" rating and a $85.00 price target on the stock. Evercore ISI lowered their price target on shares of Hologic from $76.00 to $73.00 and set an "in-line" rating for the company in a report on Thursday, February 6th. Raymond James reissued an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Royal Bank of Canada cut their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Finally, Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Up 1.1 %

Shares of NASDAQ HOLX traded up $0.68 during midday trading on Wednesday, reaching $61.48. 1,465,933 shares of the stock were exchanged, compared to its average volume of 1,756,362. Hologic, Inc. has a 12 month low of $60.34 and a 12 month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $13.80 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 2.14 and a beta of 0.97. The business has a 50-day simple moving average of $65.70 and a two-hundred day simple moving average of $73.66.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.